Ardent Health Partners stock hits 52-week low at 10.47 USD

Ardent Health Partners LLC stock reached a new 52-week low, closing at 10.47 USD. The healthcare provider, with a market capitalization of $1.53 billion, maintains strong fundamentals with a healthy current ratio of 2.12 and revenue growth of 8.91% over the last twelve months. According to InvestingPro analysis, the stock appears undervalued at current levels. This marks a significant downturn for the company, reflecting a challenging year with a 41.4% decrease in its stock price over the past 12 months. The healthcare provider has faced various market pressures and operational challenges that have contributed to this decline, pushing its stock to its lowest point in the past year. Investors are closely monitoring the company’s next steps to determine if it can recover from this downturn. For deeper insights into Ardent Health’s valuation and future prospects, InvestingPro subscribers can access comprehensive analysis, including 7 additional ProTips and a detailed Pro Research Report covering key financial metrics and growth indicators.

In other recent news, Ardent Health Partners reported a financial performance that met market expectations, with total revenue reaching $1.5 billion, a 4% increase compared to the previous year. The company’s adjusted EBITDA was noted at $98 million, surpassing analyst predictions by $2 million. Loop Capital Markets responded by lowering its price target for Ardent Health to $19.00 while maintaining a Buy rating, indicating continued confidence in the company’s prospects. Conversely, BofA Securities downgraded Ardent Health from Neutral to Underperform due to anticipated challenges from Medicaid and ACA exchange cuts, which may impact volume growth and increase bad debt. Meanwhile, KeyBanc maintained an Overweight rating on Ardent Health, highlighting optimism about potential legislative changes that could mitigate Medicaid provider tax cuts. Additionally, Ardent Health announced a rebranding initiative, changing its name to Ardent Health, Inc., effective June 2025, to enhance brand clarity. The company also appointed Chris Schoeplein as Chief Development Officer, who will focus on growth initiatives such as acquisitions and partnerships. Schoeplein brings significant experience from his previous role at Kaufman Hall, where he advised health systems on mergers and acquisitions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.